Search results for "Pulmonary capillary hemangiomatosis"

showing 2 items of 2 documents

Comprehensive three‐dimensional morphology of neoangiogenesis in pulmonary veno‐occlusive disease and pulmonary capillary hemangiomatosis

2019

Abstract Pulmonary veno‐occlusive disease (PVOD) is a rare lung disease characterized by fibrotic narrowing of pulmonary veins leading to pulmonary hypertension (PH) and finally to death by right heart failure. PVOD is often accompanied by pulmonary capillary hemangiomatosis (PCH), a marked abnormal proliferation of pulmonary capillaries. Both morphological patterns often occur together and are thought to be distinct manifestations of the same disease process and accordingly are classified together in group 1′ of the Nice classification of PH. The underlying mechanisms of these aberrant remodeling processes remain poorly understood. In this study, we investigated the three‐dimensional struc…

Pathologymedicine.medical_specialtyLung NeoplasmsHypertension Pulmonarypulmonary veno‐occlusive diseasePulmonary capillary hemangiomatosis030204 cardiovascular system & hematologypulmonary capillary hemangiomatosisPathology and Forensic Medicine03 medical and health sciencesThree dimensional morphology0302 clinical medicineRight heart failurepulmonary hypertensionmedicinelcsh:PathologyHumansHemangioma CapillaryLungNeovascularization Pathologicbusiness.industryBrief Definitive Reportintussusceptive neoangiogenesismedicine.diseasePulmonary hypertension3. Good healthmedicine.anatomical_structurePulmonary VeinsLung disease030220 oncology & carcinogenesisPulmonary Veno-Occlusive DiseaseImmunohistochemistryPulmonary Veno-Occlusive Diseasebusinesspulmonary vascular remodelinglcsh:RB1-214The Journal of Pathology: Clinical Research
researchProduct

Blood pressure variability and cardiovascular risk in 9 eastern european countries: data from the BP-Care study

2015

Methods: Total 327 patients were enrolled from 2008 to 2011 in the Korean registry program. They met the criteria of PAH and we investigated the clinical data, the medication prescribed and survival status et al. Results: Their mean age was 40.8 15.8years with female /male patient ratio of 2.7:1. The patients in WHO I/II were 32.4% and WHO III/IV were 67.6%. The peak/mean pulmonary arterial pressure was 86.3/ 56.6 mmHg. Idiopathic PAH (22%), connective tissue disease (24%) and congenital heart disease (46%) were predominant. Small number of patients with familial PAH, portal hypertension, HIV infection, pulmonary capillary hemangiomatosis (PCH) existed. The patients described bosentan were …

medicine.medical_specialtyHeart diseasebusiness.industrySildenafilPulmonary capillary hemangiomatosismedicine.diseaseBosentanEastern europeanchemistry.chemical_compoundBlood pressurechemistryInternal medicineInternal MedicinemedicineCardiology and Cardiovascular MedicinebusinessSurvival ratemedicine.drugCohort studyJournal of the American Society of Hypertension
researchProduct